Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The analysis of the quarterly financial ratios reveals several notable trends over the reported periods.

Return on Assets (ROA)
Initially, ROA showed a robust upward trend, increasing from 22.53% in the first quarter of 2021 to a peak of 31.75% by the end of that year. Subsequently, there was a marked decline through 2022, bottoming out around 11.95% to 14.02% in early 2023. From mid-2023 onwards, ROA stabilized with moderate fluctuations, remaining roughly between 11% and 12.5% up to the third quarter of 2025. This suggests initial improvements in asset utilization efficiency were followed by a significant reduction and subsequent stabilization at a lower performance level.
Financial Leverage
Financial leverage exhibited a gradual but consistent reduction over the entire period, declining from 1.48 in early 2021 to approximately 1.27–1.30 in the later quarters up to 2025. The ratio remained relatively stable with only minor variations in the 1.27 to 1.30 range from 2022 onwards. This indicates a trend toward slightly lower reliance on debt or financial obligations relative to equity, suggesting a modest deleveraging or a more conservative capital structure over time.
Return on Equity (ROE)
ROE displayed a pattern similar to ROA but with higher volatility and magnitude. The metric increased sharply from 33.43% in early 2021, reaching a high of 43.03% by the end of 2021. Following this peak, there was a pronounced decrease over the next 18 months, falling to approximately 14.29% by the first quarter of 2024. After this decline, ROE showed modest fluctuations and slight recovery, hovering around 14% to 16% through late 2025. This indicates that shareholder returns were initially strong but experienced a notable downturn and then settled into a more moderate level.

Overall, the financial ratios demonstrate a phase of strong performance up to late 2021, followed by a significant moderation in profitability and returns on both assets and equity throughout 2022 and thereafter. The modest decline in financial leverage suggests a conservative approach to financing amid changing profitability. The stabilization of returns in recent periods could indicate the establishment of a new performance baseline.


Three-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The analysis of the quarterly financial ratios reveals notable trends in profitability, operational efficiency, leverage, and overall equity returns over the reported periods.

Net Profit Margin

The net profit margin exhibits a peak in late 2021, reaching values above 50%, indicating strong profitability during that period. Subsequently, the margin shows a gradual decline throughout 2022 and stabilizes in the 30% range from early 2023 onward. Minor fluctuations are observed within this range, but the margin does not return to the elevated levels seen in 2021, suggesting a reduction in profit efficiency relative to revenues.

Asset Turnover

Asset turnover, reflecting the efficiency in utilizing assets to generate revenue, remains relatively steady around 0.5 to 0.6 in early periods, but shows a slow and consistent decline starting from the end of 2021. By the most recent quarters, it has decreased to approximately 0.35, which indicates diminishing efficiency in asset utilization over time.

Financial Leverage

Financial leverage ratios are relatively stable across the periods, fluctuating narrowly between approximately 1.3 and 1.5. There is a slight downward trend from 1.48 in early 2021 to about 1.27-1.3 in the latest quarters, reflecting a modest reduction in reliance on debt or borrowed funds relative to equity within the capital structure.

Return on Equity (ROE)

Return on equity peaked near 43% in late 2021 but then experienced a marked decline into 2022, falling below 20% and reaching a low near 14% in the most recent periods. This trend indicates diminishing profitability from shareholders' perspective despite stable financial leverage. The decline in ROE appears to be driven mainly by decreasing profit margins and asset turnover ratios, which temper net income generation relative to equity.

Overall, the data indicates that after a period of strong profitability and operational efficiency in 2021, the company faces challenges in sustaining such performance into subsequent years. Profit margins and asset utilization have declined steadily, impacting return on equity despite stable leverage. The trends suggest the need for enhanced operational initiatives to regain efficiency and profitability levels witnessed in the earlier periods.


Five-Component Disaggregation of ROE

Regeneron Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Sep 30, 2025 = × × × ×
Jun 30, 2025 = × × × ×
Mar 31, 2025 = × × × ×
Dec 31, 2024 = × × × ×
Sep 30, 2024 = × × × ×
Jun 30, 2024 = × × × ×
Mar 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Sep 30, 2023 = × × × ×
Jun 30, 2023 = × × × ×
Mar 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Sep 30, 2022 = × × × ×
Jun 30, 2022 = × × × ×
Mar 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Sep 30, 2021 = × × × ×
Jun 30, 2021 = × × × ×
Mar 31, 2021 = × × × ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Tax Burden
The tax burden remained relatively stable with minor fluctuations, starting at 0.91 and generally sustaining a level between 0.86 and 0.95 over the periods. It peaked at 0.95 and then slightly declined, indicating a consistent proportion of earnings retained after tax over time.
Interest Burden
This ratio exhibited very little variation, hovering around 0.98 to 0.99 throughout the timeline. This stability suggests limited impact from interest expenses on earnings before tax, indicating low financial costs or steady interest expense relative to earnings.
EBIT Margin
The EBIT margin showed a noticeable downward trend. It started at a high of approximately 59.85% but declined progressively to around 31.4 - 36.4% in the later periods. This suggests diminishing operating profitability as a percentage of revenue, possibly reflecting increased operating expenses or reduced pricing power.
Asset Turnover
Asset turnover declined steadily from 0.63 to about 0.35–0.41 over the course of the periods. This diminishing efficiency indicates the company generated less revenue per unit of assets over time, which could signify underutilized assets or growth in asset base not matched by revenue increases.
Financial Leverage
Financial leverage remained relatively constant in a narrow range around 1.27 to 1.48, indicating stable use of debt financing relative to equity. This consistency implies no significant shifts in capital structure or leverage-related risk across the reported periods.
Return on Equity (ROE)
ROE declined markedly from a peak above 43% to a range closer to 14–17% in the latest periods, mirroring the declines in EBIT margin and asset turnover. This decrease reflects reduced profitability and efficiency in utilizing shareholders' equity to generate earnings, signaling potential pressures on overall equity returns.

Two-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×
Dec 31, 2021 = ×
Sep 30, 2021 = ×
Jun 30, 2021 = ×
Mar 31, 2021 = ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The financial data reveals several noteworthy trends in key profitability and efficiency metrics over the examined periods.

Net Profit Margin
The net profit margin exhibited a strong performance initially, with a peak around the third quarter of 2021 exceeding 50%. This margin showed a gradual decline moving into 2022, dropping to the mid-30% range by the end of that year. Throughout 2023 and into 2025, the margin stabilized somewhat, consistently hovering around the low 30% range. This suggests a period of margin contraction following the high levels in 2021, but with relative consistency and modest improvement in some quarters towards the end of the timeline.
Asset Turnover
Asset turnover showed a decreasing trend throughout the periods. Beginning at approximately 0.52 in the first quarter of 2021, the ratio increased briefly to 0.63 within the same year but then steadily declined over the subsequent years. From 2022 onward, the ratio dropped consistently, reaching approximately 0.35 by the end of the observed periods in 2025. This pattern indicates a gradual reduction in the efficiency with which assets generate revenue over time.
Return on Assets (ROA)
ROA mirrored some of the trends seen in net profit margin but with more pronounced fluctuations. The ratio rose from around 22.5% in early 2021 to near 31.75% by the end of that year, reflecting robust asset profitability. However, from 2022 onwards, there was a clear downward trajectory, dropping to about 14% by the end of 2022 and further declining throughout 2023. In the later periods, ROA stabilized in the low double-digit range, approximately between 11% and 12%. This decrease indicates a significant reduction in overall asset profitability after 2021, paralleling the declines seen in margin and asset turnover.

In summary, the data indicates that despite a strong profitability and asset efficiency performance in 2021, these metrics have experienced a sustained decline in the following years, stabilizing at lower levels through 2023 to 2025. The reduction in asset turnover suggests a decreased efficiency in using assets to generate revenue, which, combined with the decline in net profit margin and ROA, points to mounting challenges in maintaining prior levels of profitability and asset effectiveness.


Four-Component Disaggregation of ROA

Regeneron Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Sep 30, 2025 = × × ×
Jun 30, 2025 = × × ×
Mar 31, 2025 = × × ×
Dec 31, 2024 = × × ×
Sep 30, 2024 = × × ×
Jun 30, 2024 = × × ×
Mar 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Sep 30, 2023 = × × ×
Jun 30, 2023 = × × ×
Mar 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Sep 30, 2022 = × × ×
Jun 30, 2022 = × × ×
Mar 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Sep 30, 2021 = × × ×
Jun 30, 2021 = × × ×
Mar 31, 2021 = × × ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The analysis of the financial ratios over the given quarterly periods reveals several notable trends and shifts in the company's profitability and operational efficiency.

Tax Burden
The tax burden ratio remained relatively stable, fluctuating between 0.86 and 0.95 throughout the observed periods. It showed a slight upward trend from early 2021 through early 2024, peaking around 0.95, before experiencing a mild decrease towards the end of the data range. This suggests a relatively consistent, though slightly increasing, effective tax rate impacting net profit margins.
Interest Burden
The interest burden ratio remained nearly constant at approximately 0.99 across all quarters. This consistency points to stable interest expenses relative to earnings before interest and taxes, indicating that the company's financing costs have been well-managed and have not materially affected profitability.
EBIT Margin
The Earnings Before Interest and Taxes (EBIT) margin exhibited a declining trend over the examined quarters. Starting at approximately 48.49% in the first quarter of 2021, the margin peaked near 59.85% during late 2021 but then steadily decreased to about 31-36% in the 2023-2025 period. This decline could indicate rising operating costs, pricing pressures, or changes in sales mix negatively impacting operational profitability.
Asset Turnover
Asset turnover, a measure of the efficiency with which the company uses its assets to generate sales, showed a gradual decrease. Beginning from around 0.52 in early 2021, it peaked near 0.63 mid-year 2021 but steadily declined to approximately 0.35 by the third quarter of 2025. This downward trend implies reduced efficiency in asset utilization, which may signal either an increase in asset base not matched by corresponding sales growth or diminished sales productivity.
Return on Assets (ROA)
Return on Assets mirrored the declining operational efficiency trends, decreasing from about 22.53% in early 2021 to around 11.4% by late 2025. The peak was near 31.75% at the end of 2021, after which ROA consistently trended downward. This reduction reflects the combined effects of reduced EBIT margins and declining asset turnover, pointing to lower overall profitability relative to the asset base.

Disaggregation of Net Profit Margin

Regeneron Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×
Dec 31, 2021 = × ×
Sep 30, 2021 = × ×
Jun 30, 2021 = × ×
Mar 31, 2021 = × ×

Based on: 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


Tax Burden Trend
The tax burden ratio demonstrates a relatively stable pattern over the observed periods, fluctuating mildly between 0.86 and 0.95. Initially, a slight decline is noticeable in mid-2021, followed by a gradual upward movement peaking around early 2024 at approximately 0.95. Subsequently, it shows a modest decrease towards 0.89 by the end of the forecasted periods. This indicates that the proportion of income tax relative to earnings before tax remains fairly consistent with minor variations.
Interest Burden Trend
The interest burden ratio remains virtually steady throughout the timeline, consistently near the 0.99 level. Minor decreases to 0.98 are observed in late 2022 and early 2023, but the ratio promptly returns to 0.99. This stability suggests that interest expenses have little impact on operating income, indicating minimal fluctuations in debt servicing costs relative to operating profit.
EBIT Margin Analysis
The EBIT margin reveals a clear downward trend from early 2021 through late 2023, declining from a high of 59.85% to a trough near 31.4%. This substantial reduction in operating profitability indicates increased operating costs or pricing pressures over this period. Notably, starting in early 2024, there is a moderate recovery with the margin rising to around 36.41% by the latest period, suggesting an improvement in operating efficiency or better cost management in more recent quarters.
Net Profit Margin Analysis
The net profit margin closely mirrors the EBIT margin's trajectory, descending from over 50% in early 2021 to below 30% during late 2023. This decline reflects diminishing overall profitability after accounting for taxes and interest. However, beginning in 2024, the net margin demonstrates signs of recovery, increasing steadily to about 32.13% by the most recent period. This improvement implies enhanced control over non-operating expenses or tax efficiencies that positively influence the bottom line.
Overall Insights
Collectively, the data suggests a period of declining profitability between 2021 and 2023, with significant compression in both operating and net margins. The stable interest burden indicates that financial leverage or interest costs were not major contributors to profitability changes. The tax burden's mild fluctuations have some impact on net profitability but remain generally steady. Recent trends from 2024 onward imply gradual stabilization and improvement in operational performance and net profitability, which could reflect strategic adjustments or favorable market conditions.